Paul Stoffels, Johnson & Johnson

2013 pay package: $7.8 million
2012 pay package: $7.3 million
Change: +7%
2013 compensation: $952,923 in salary; $2.6 million in stock awards; $1.1 million in option awards; $2.4 million in non-equity incentive plan compensation, $404,802 in other compensation; a $357,000 change in pension value and deferred compensation earnings

Paul Stoffels jumped to third on this list in his first full year at helm of Johnson & Johnson's ($JNJ) expansive R&D department, banking a sizable raise after taking over in October 2012. That period has seen J&J pick up weighty FDA approvals for the expected blockbuster cancer therapy Imbruvica (ibrutinib), diabetes contender Invokana (canagliflozin) and hepatitis C treatment Olysio (simeprevir).

But what sets Stoffels apart from his contemporaries is an open-armed approach to external R&D, a trend he began years before taking the chief scientific officer spot at J&J.

While the industry has long been moving away from the insular drug development paradigms of yesteryear, J&J is ahead of the curve: As The Wall Street Journal noted in March, in 2012, about one-third of Big Pharma's pipeline was discovered by another company; for J&J, the proportion was 50%.

That's a credit to Stoffels, who, in 2009, spearheaded a program called Project Playbook, under which J&J designated a few promising disease targets and then amassed all the relevant information on any drugs under development to treat them. From there, the company built a matrix of potential licensing targets sorted by safety, efficacy and phase of development, and it was through Project Playbook that J&J first found Pharmacyclics ($PCYC), the developer of ibrutinib. The same method led to daratumumab, a multiple myeloma treatment J&J licensed from Genmab for up to $1.1 billion, and ARN-509, the prostate cancer-fighting star of the company's $1 billion deal for Aragon Pharmaceuticals.

Now Stoffels and co. are at work casting an even wider net, setting up dealmaking outposts at biotech hotspots around the globe and incubating potential partners through no-strings-attached residencies at the expanding Janssen Labs.

- read the proxy statement (PDF)

For more:
J&J makes an R&D splash with $42M venture play, biotech collaborations
In revamped early-stage drive, J&J's Stoffels lets his biotech flag fly

Paul Stoffels, Johnson & Johnson

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.